Top

Published in:

01-02-2014 | Review Paper

Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies

Authors: Soumit K. Basu, Scot C. Remick, Manish Monga, Laura F. Gibson

Published in: Clinical & Experimental Metastasis | Issue 2/2014

Abstract

Various malignancies invade the CNS sanctuary site, accounting for the vast majority of CNS neoplastic foci and contributing to significant morbidity as well as mortality. The blood–brain barrier (BBB) exhibits considerable impermeability to chemotherapeutic agents, severely limiting therapeutic options available for patients developing metastatic CNS involvement, accounting for poor outcomes. The mechanisms by which malignant cells breach the highly exclusive BBB and subsequently survive in this unique anatomical site remain poorly understood, with most of the current knowledge stemming from nonmalignant and solid malignancy models. While solid and hematologic malignancies may face different challenges once within the CNS (e.g., solid tumor parenchymal metastasis compared to masses/nodules/leptomeningeal disease in hematologic malignancies), commonality exists in the process of migrating across the BBB from the circulation. Specifically considering this last point, this review aims to survey the current mechanistic knowledge regarding malignant migration across the BBB, necessarily emphasizing the better studied solid tumor and nonmalignant models with the intention of highlighting both the current knowledge gap and additional work required to effectively consider how hematopoietic malignancies breach the CNS.

Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29:533–540PubMedCrossRef

Gavrilovic IT, Posner JB (2005) Brain metastases: epidemiology and pathophysiology. J Neurooncol 75:5–14. doi:10.1007/s11060-004-8093-6 PubMedCrossRef

Alexandru D, Bota DA, Linskey ME (2012) Epidemiology of central nervous system metastases. Prog Neurol Surg 25:13–29. doi:10.1159/000331167 PubMedCrossRef

Eichler AF, Chung E, Kodack DP et al (2011) The biology of brain metastases-translation to new therapies. Nat Rev Clin Oncol 8:344–356. doi:10.1038/nrclinonc.2011.58 PubMedCentralPubMed

Jellinger K, Radiaszkiewicz T (1976) Involvement of the central nervous system in malignant lymphomas. Virchows Arch A Pathol Anat Histol 370:345–362PubMedCrossRef

Yi JH, Kim JH, Baek KK et al (2011) Elevated LDH and paranasal sinus involvement are risk factors for central nervous system involvement in patients with peripheral T-cell lymphoma. Ann Oncol 22:1636–1643. doi:10.1093/annonc/mdq645 PubMedCrossRef

Pui C-H, Thiel E (2009) Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 36:S2–S16. doi:10.1053/j.seminoncol.2009.05.002 PubMedCentralPubMedCrossRef

Hollender A, Kvaloy S, Nome O et al (2002) Central nervous system involvement following diagnosis of non-Hodgkin’s lymphoma: a risk model. Ann Oncol 13:1099–1107PubMedCrossRef

Lazarus HM, Richards SM, Chopra R et al (2006) Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood 108:465–472. doi:10.1182/blood-2005-11-4666 PubMedCrossRef

10.

Law IP, Blom J (1976) Adult central nervous system leukemia: incidence and clinicopathologic features. South Med J 69:1054–1057PubMedCrossRef

11.

Furák J, Troján I, Szöke T et al (2005) Lung cancer and its operable brain metastasis: survival rate and staging problems. Ann Thorac Surg 79:241–247. doi:10.1016/j.athoracsur.2004.06.051 discussion 241–247PubMedCrossRef

12.

Chamberlain MC (2010) Leptomeningeal metastasis. Curr Opin Oncol 22:627–635. doi:10.1097/CCO.0b013e32833de986 PubMedCrossRef

13.

Chiou S-M (2012) Survival of brain metastatic patients treated with gamma knife radiosurgery alone. Clin Neurol Neurosurg. doi:10.1016/j.clineuro.2012.05.018 PubMed

14.

Eichler AF, Kuter I, Ryan P et al (2008) Survival in patients with brain metastases from breast cancer: the importance of HER-2 status. Cancer 112:2359–2367. doi:10.1002/cncr.23468 PubMedCrossRef

15.

Knisely JPS, Yu JB, Flanigan J et al (2012) Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg. doi:10.3171/2012.5.JNS111929 PubMed

16.

Pui C-H, Howard SC (2008) Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 9:257–268. doi:10.1016/S1470-2045(08)70070-6 PubMedCrossRef

17.

Ness KK, Hudson MM, Pui C-H et al (2012) Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses. Cancer 118:828–838. doi:10.1002/cncr.26337 PubMedCentralPubMedCrossRef

18.

Huber JD, Egleton RD, Davis TP (2001) Molecular physiology and pathophysiology of tight junctions in the blood–brain barrier. Trends Neurosci 24:719–725PubMedCrossRef

19.

Ransohoff RM, Kivisäkk P, Kidd G (2003) Three or more routes for leukocyte migration into the central nervous system. Nat Rev Immunol 3:569–581. doi:10.1038/nri1130 PubMedCrossRef

20.

Redzic Z (2011) Molecular biology of the blood–brain and the blood–cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 8:3. doi:10.1186/2045-8118-8-3 PubMedCentralPubMedCrossRef

21.

Goldmann E (1909) Die a¨ ussere und innere Sekretion des gesunden und kranken Organismus im Lichte der “vitalen Farbung”. Beitr klin Chir 64:192–265

22.

Pardridge WM (2007) Blood–brain barrier delivery. Drug Discov Today 12:54–61. doi:10.1016/j.drudis.2006.10.013 PubMedCrossRef

23.

Hickey WF (1999) Leukocyte traffic in the central nervous system: the participants and their roles. Semin Immunol 11:125–137. doi:10.1006/smim 1999.0168PubMedCrossRef

24.

Zlokovic BV (2008) The blood–brain barrier in health and chronic neurodegenerative disorders. Neuron 57:178–201. doi:10.1016/j.neuron.2008.01.003 PubMedCrossRef

25.

Williams DW, Eugenin EA, Calderon TM, Berman JW (2012) Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol 91:401–415. doi:10.1189/jlb.0811394 PubMedCrossRef

26.

Delattre JY, Krol G, Thaler HT, Posner JB (1988) Distribution of brain metastases. Arch Neurol 45:741–744PubMedCrossRef

27.

Kienast Y, von Baumgarten L, Fuhrmann M et al (2010) Real-time imaging reveals the single steps of brain metastasis formation. Nat Med 16:116–122. doi:10.1038/nm.2072 PubMedCrossRef

28.

Van Besien K, Ha CS, Murphy S et al (1998) Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 91:1178–1184PubMed

29.

Garrido SM, Appelbaum FR, Willman CL, Banker DE (2001) Acute myeloid leukemia cells are protected from spontaneous and drug-induced apoptosis by direct contact with a human bone marrow stromal cell line (HS-5). Exp Hematol 29:448–457PubMedCrossRef

30.

Hazlehurst LA, Valkov N, Wisner L et al (2001) Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells. Blood 98:1897–1903PubMedCrossRef

31.

Becker PS, Kopecky KJ, Wilks AN et al (2009) Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 113:866–874. doi:10.1182/blood-2007-12-124818 PubMedCrossRef

32.

Wang L, O’Leary H, Fortney J, Gibson LF (2007) Ph+/VE-cadherin+ identifies a stem cell like population of acute lymphoblastic leukemia sustained by bone marrow niche cells. Blood 110:3334–3344. doi:10.1182/blood-2007-01-068122 PubMedCrossRef

33.

Matsunaga T, Takemoto N, Sato T et al (2003) Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat Med 9:1158–1165. doi:10.1038/nm909 PubMedCrossRef

34.

Matsunaga T, Fukai F, Miura S et al (2008) Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia. Leukemia 22:353–360. doi:10.1038/sj.leu.2405017 PubMedCrossRef

35.

Nervi B, Ramirez P, Rettig MP et al (2009) Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 113:6206–6214. doi:10.1182/blood-2008-06-162123 PubMedCrossRef

36.

Zeng Z, Samudio IJ, Munsell M et al (2006) Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias. Mol Cancer Ther 5:3113–3121. doi:10.1158/1535-7163.MCT-06-0228 PubMedCrossRef

37.

Meads MB, Hazlehurst LA, Dalton WS (2008) The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin Cancer Res 14:2519–2526. doi:10.1158/1078-0432.CCR-07-2223 PubMedCrossRef

38.

Ravandi F, Cortes J, Estrov Z et al (2002) CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia. Leuk Res 26:643–649PubMedCrossRef

39.

Carbonell WS, Ansorge O, Sibson N, Muschel R (2009) The vascular basement membrane as “soil” in brain metastasis. PLoS One 4:e5857. doi:10.1371/journal.pone.0005857 PubMedCentralPubMedCrossRef

40.

Wu YJ, Muldoon LL, Gahramanov S et al (2012) Targeting α(V)-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model. J Neurooncol 110:27–36. doi:10.1007/s11060-012-0942-0 PubMedCentralPubMedCrossRef

41.

Rodrigues-Ferreira S, Abdelkarim M, Dillenburg-Pilla P et al (2012) Angiotensin II facilitates breast cancer cell migration and metastasis. PLoS One 7:e35667. doi:10.1371/journal.pone.0035667 PubMedCentralPubMedCrossRef

42.

Weksler BB, Subileau EA, Perrière N et al (2005) Blood–brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872–1874. doi:10.1096/fj.04-3458fje PubMed

43.

Chen WT (1989) Proteolytic activity of specialized surface protrusions formed at rosette contact sites of transformed cells. J Exp Zool 251:167–185. doi:10.1002/jez.1402510206 PubMedCrossRef

44.

Mueller SC, Chen WT (1991) Cellular invasion into matrix beads: localization of beta 1 integrins and fibronectin to the invadopodia. J Cell Sci 99(Pt 2):213–225PubMed

45.

Nie F, Yang J, Wen S et al (2012) Involvement of epidermal growth factor receptor overexpression in the promotion of breast cancer brain metastasis. Cancer. doi:10.1002/cncr.27553 PubMed

46.

Gabos Z, Sinha R, Hanson J et al (2006) Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer. J Clin Oncol 24:5658–5663. doi:10.1200/JCO.2006.07.0250 PubMedCrossRef

47.

Lai R, Dang CT, Malkin MG, Abrey LE (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:810–816. doi:10.1002/cncr.20418 PubMedCrossRef

48.

Daubon T, Rochelle T, Bourmeyster N, Génot E (2012) Invadopodia and rolling-type motility are specific features of highly invasive p190(bcr-abl) leukemic cells. Eur J Cell Biol 91:978–987. doi:10.1016/j.ejcb.2012.04.006 PubMedCrossRef

49.

Kontogianni K, Nicholson AG, Butcher D, Sheppard MN (2005) CD56: a useful tool for the diagnosis of small cell lung carcinomas on biopsies with extensive crush artefact. J Clin Pathol 58:978–980. doi:10.1136/jcp.2004.023044 PubMedCrossRef

50.

Yun J-P, Xiang J, Hou J-H et al (2005) Expression of CD56, as a potential diagnostic marker, in small cell carcinoma. Ai Zheng 24:1140–1143PubMed

51.

Argaw AT, Gurfein BT, Zhang Y et al (2009) VEGF-mediated disruption of endothelial CLN-5 promotes blood-brain barrier breakdown. Proc Natl Acad Sci USA 106:1977–1982. doi:10.1073/pnas.0808698106 PubMedCrossRef

52.

Feng S, Cen J, Huang Y et al (2011) Matrix metalloproteinase-2 and -9 secreted by leukemic cells increase the permeability of blood–brain barrier by disrupting tight junction proteins. PLoS One 6:e20599. doi:10.1371/journal.pone.0020599 PubMedCentralPubMedCrossRef

53.

Yamaguchi H (2012) Pathological roles of invadopodia in cancer invasion and metastasis. Eur J Cell Biol. doi:10.1016/j.ejcb.2012.04.005

54.

Lee KY, Kim Y-J, Yoo H et al (2011) Human brain endothelial cell-derived COX-2 facilitates extravasation of breast cancer cells across the blood–brain barrier. Anticancer Res 31:4307–4313PubMed

55.

Fan J, Cai B, Zeng M et al (2011) Integrin β4 signaling promotes mammary tumor cell adhesion to brain microvascular endothelium by inducing ErbB2-mediated secretion of VEGF. Ann Biomed Eng 39:2223–2241. doi:10.1007/s10439-011-0321-6 PubMedCrossRef

56.

Feng S, Huang Y, Chen Z (2011) Does VEGF secreted by leukemic cells increase the permeability of blood-brain barrier by disrupting tight-junction proteins in central nervous system leukemia? Med Hypotheses 76:618–621. doi:10.1016/j.mehy.2010.12.001 PubMedCrossRef

57.

Markovic A, MacKenzie KL, Lock RB (2012) Induction of vascular endothelial growth factor secretion by childhood acute lymphoblastic leukemia cells via the FLT-3 signaling pathway. Mol Cancer Ther 11:183–193. doi:10.1158/1535-7163.MCT-11-0503 PubMedCrossRef

58.

Shirasaki R, Tashiro H, Oka Y et al (2011) Vascular endothelial growth factor-C and its receptor type-3 expressed in acute lymphocytic leukemia cases with t(1;19). Int J Hematol 94:203–208. doi:10.1007/s12185-011-0889-5 PubMedCrossRef

59.

McGowan PM, Simedrea C, Ribot EJ et al (2011) Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res 9:834–844. doi:10.1158/1541-7786.MCR-10-0457 PubMedCentralPubMedCrossRef

60.

Bos PD, Zhang XH-F, Nadal C et al (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459:1005–1009. doi:10.1038/nature08021 PubMedCentralPubMedCrossRef

61.

Harrell JC, Prat A, Parker JS et al (2012) Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat 132:523–535. doi:10.1007/s10549-011-1619-7 PubMedCentralPubMedCrossRef

62.

Buonamici S, Trimarchi T, Ruocco MG et al (2009) CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459:1000–1004. doi:10.1038/nature08020 PubMedCentralPubMedCrossRef

63.

Eugenin EA, Osiecki K, Lopez L et al (2006) CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 26:1098–1106. doi:10.1523/JNEUROSCI.3863-05.2006 PubMedCrossRef

64.

Eisenkraft A, Keidan I, Bielorai B et al (2006) MCP-1 in the cerebrospinal fluid of children with acute lymphoblastic leukemia. Leuk Res 30:1259–1261. doi:10.1016/j.leukres.2006.01.017 PubMedCrossRef

65.

Akers SM, Rellick SL, Fortney JE, Gibson LF (2011) Cellular elements of the subarachnoid space promote ALL survival during chemotherapy. Leuk Res 35:705–711. doi:10.1016/j.leukres.2010.12.031 PubMedCentralPubMedCrossRef

66.

Akers SM, O’Leary HA, Minnear FL et al (2010) VE-cadherin and PECAM-1 enhance ALL migration across brain microvascular endothelial cell monolayers. Exp Hematol 38:733–743. doi:10.1016/j.exphem.2010.05.001 PubMedCentralPubMedCrossRef

67.

Gimferrer I, Calvo M, Mittelbrunn M et al (2004) Relevance of CD6-mediated interactions in T cell activation and proliferation. J Immunol 173:2262–2270PubMed

68.

Fu Y, Zheng Y, Li K et al (2012) Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9. Biotechnol Lett 34:441–446. doi:10.1007/s10529-011-0800-8 PubMedCrossRef

69.

Shuman Moss LA, Jensen-Taubman S, Stetler-Stevenson WG (2012) Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol. doi:10.1016/j.ajpath.2012.08.044 PubMed

70.

Vérollet C, Charrière GM, Labrousse A et al (2011) Extracellular proteolysis in macrophage migration: losing grip for a breakthrough. Eur J Immunol 41:2805–2813. doi:10.1002/eji.201141538 PubMedCrossRef

71.

Lin Q, Balasubramanian K, Fan D et al (2010) Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. Neoplasia 12:748–754PubMedCentralPubMed

72.

Fidler IJ (2011) The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 21:107–112. doi:10.1016/j.semcancer.2010.12.009 PubMedCrossRef

73.

Pukrop T, Dehghani F, Chuang H-N et al (2010) Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia 58:1477–1489. doi:10.1002/glia.21022 PubMed

74.

Yano S, Shinohara H, Herbst RS et al (2000) Expression of vascular endothelial growth factor is necessary but not sufficient for production and growth of brain metastasis. Cancer Res 60:4959–4967PubMed

75.

Gratzinger D, Zhao S, Tibshirani RJ et al (2008) Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy. Lab Invest 88:38–47. doi:10.1038/labinvest.3700697 PubMedCrossRef

76.

Kim JA, Kim SJ, Do I-G et al (2011) Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis? Leuk Lymphoma 52:205–213. doi:10.3109/10428194.2010.542261 PubMedCrossRef

77.

Todorovic M, Radisavljevic Z, Balint B et al (2012) Increased angiogenesis-associated poor outcome in acute lymphoblastic leukemia: a single center study. Appl Immunohistochem Mol Morphol 20:488–493. doi:10.1097/PAI.0b013e3182414c3b PubMedCrossRef

78.

Tang Y-T, Jiang F, Guo L et al (2013) Expression and significance of vascular endothelial growth factor A and C in leukemia central nervous system metastasis. Leuk Res 37:359–366. doi:10.1016/j.leukres.2012.10.008 PubMedCrossRef

79.

Cortes J, O’Brien SM, Pierce S et al (1995) The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 86:2091–2097PubMed

80.

Gökbuget N, Hoelzer D (2006) Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 133–141. doi: 10.1182/asheducation-2006.1.133

81.

Pui C-H (2006) Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program 142–146. doi: 10.1182/asheducation-2006.1.142

82.

Van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E (2008) Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma 49(Suppl 1):52–58. doi:10.1080/10428190802311458 PubMedCrossRef

83.

Avilés A, Delgado S, Nambo MJ et al (2005) Primary breast lymphoma: results of a controlled clinical trial. Oncology 69:256–260. doi:10.1159/000088333 PubMedCrossRef

84.

Montserrat E, Bosch F, López-Guillermo A et al (1996) CNS involvement in mantle-cell lymphoma. J Clin Oncol 14:941–944PubMed

85.

Vitolo U, Chiappella A, Ferreri AJM et al (2011) First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol 29:2766–2772. doi:10.1200/JCO.2010.31.4187 PubMedCrossRef

86.

Zucca E, Conconi A, Mughal TI et al (2003) Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 21:20–27PubMedCrossRef

87.

Hormigo A, Abrey L, Heinemann M-H, DeAngelis LM (2004) Ocular presentation of primary central nervous system lymphoma: diagnosis and treatment. Br J Haematol 126:202–208. doi:10.1111/j.1365-2141.2004.05028.x PubMedCrossRef

88.

Nagpal S, Glantz MJ, Recht L (2010) Treatment and prevention of secondary CNS lymphoma. Semin Neurol 30:263–272. doi:10.1055/s-0030-1255222 PubMedCrossRef

89.

Gore EM, Bae K, Wong SJ et al (2011) Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small-cell lung cancer: primary analysis of radiation therapy oncology group study RTOG 0214. J Clin Oncol 29:272–278. doi:10.1200/JCO.2010.29.1609 PubMedCrossRef

90.

Sun A, Bae K, Gore EM et al (2011) Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis. J Clin Oncol 29:279–286. doi:10.1200/JCO.2010.29.6053 PubMedCrossRef

91.

Viani GA, Boin AC, Ikeda VY et al (2012) Thirty years of prophylactic cranial irradiation in patients with small cell lung cancer: a meta-analysis of randomized clinical trials. J Bras Pneumol 38:372–381PubMedCrossRef

92.

Welsh JW, Komaki R, Amini A et al (2013) Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 31:895–902. doi:10.1200/JCO.2011.40.1174 PubMedCrossRef

93.

Park SJ, Kim HT, Lee DH et al (2012) Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. Lung Cancer 77:556–560. doi:10.1016/j.lungcan.2012.05.092 PubMedCrossRef

94.

Wells SJ, Bray RA, Stempora LL, Farhi DC (1996) CD117/CD34 expression in leukemic blasts. Am J Clin Pathol 106:192–195PubMed

95.

Soffietti R, Trevisan E, Rudà R (2012) Targeted therapy in brain metastasis. Curr Opin Oncol 24:679–686. doi:10.1097/CCO.0b013e3283571a1c PubMedCrossRef

96.

Podar K, Anderson KC (2005) The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105:1383–1395. doi:10.1182/blood-2004-07-2909 PubMedCrossRef

97.

Tang Y-T, Jiang F, Guo L et al (2013) The soluble VEGF receptor 1 and 2 expression in cerebral spinal fluid as an indicator for leukemia central nervous system metastasis. J Neurooncol. doi:10.1007/s11060-013-1066-x

98.

Gupta GP, Nguyen DX, Chiang AC et al (2007) Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 446:765–770. doi:10.1038/nature05760 PubMedCrossRef

99.

Barkan D, Kleinman H, Simmons JL et al (2008) Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res 68:6241–6250. doi:10.1158/0008-5472.CAN-07-6849 PubMedCentralPubMedCrossRef

100.

Bartolotti M, Franceschi E, Brandes AA (2012) EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer. Expert Rev Anticancer Ther 12:1429–1435. doi:10.1586/era.12.121 PubMedCrossRef

Title: Breaking and entering into the CNS: clues from solid tumor and nonmalignant models with relevance to hematopoietic malignancies
Authors: Soumit K. Basu
Scot C. Remick
Manish Monga
Laura F. Gibson
Publication date: 01-02-2014
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 2/2014
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-013-9623-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

PITX2 and non-canonical Wnt pathway interaction in metastatic prostate cancer

Changes in the peripheral blood and bone marrow from untreated advanced breast cancer patients that are associated with the establishment of bone metastases

Underactivation of the adiponectin–adiponectin receptor 1 axis in clear cell renal cell carcinoma: implications for progression

RANK expression on breast cancer cells promotes skeletal metastasis

Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology

Primary 4T1 tumor resection provides critical “window of opportunity” for immunotherapy

Keynote webinar | Spotlight on antibody–drug conjugates in cancer